In Ov-CCA, patients exhibiting methylation at the DcR1 locus displayed a greater survival rate than those without methylation [8,86], indicating the potential use of recombinant TRAIL and TRAIL receptor agonists for Ov-CCA treatment. Here, TNFSF10 is linked to cholangiocarcinoma.